Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235731 | 0.85 | IRAK4 (0.42) | IRAK4F7F3SARM1SIRT2 | |
| SCHEMBL21840509 | 0.83 | IRAK4 (0.46) | IRAK4KDM4EEGLN1PDE4APDE4B | |
| SCHEMBL25482782 | 0.77 | IRAK4 (0.45) | IRAK4EGLN1PDE4APDE4BPDE4C | |
| SCHEMBL27447614 | 0.77 | IRAK4 (0.48) | IRAK4KDM4EMAP2K1PDE4A | |
| SCHEMBL6442649 | 0.74 | LTA4H (0.45) | IRAK4KDM4EMAPK14 | |
| SCHEMBL454803 | 0.73 | TGFBR1 (0.48) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL27881205 | 0.73 | MKNK1 (0.37) | IRAK4F7F3SARM1SIRT2 | |
| SCHEMBL14686184 | 0.73 | IRAK4 (0.34) | IRAK4F7F3SARM1SIRT2 | |
| SCHEMBL18048137 | 0.72 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL29416245 | 0.71 | PARP1 (0.42) | PARP1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697790-B1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-01-18 | — | — | EP | claimed |
| US-10040798-B2 | Pyrrolopyridazine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-08-07 | — | — | US | claimed |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| WO-2025126115-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| CN-119403805-A | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023237049-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
| EP-3697790-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019077517-A1 | HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| CN-102548993-B | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2014-12-10 | — | — | CN | disclosed |
| EP-2459557-B1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8415336-B2 | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-04-09 | — | — | US | disclosed |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-13 | — | — | US | disclosed |
| CN-102548993-A | Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040798-B2 | Pyrrolopyridazine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | IRAK4 1/4885F7 4840/4885F3 3362/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | IRAK4 1/4885F7 4820/4885F3 3364/4885 |
| US-20120232081-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | IRAK4 2903/4885F7 2866/4885F3 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.